Most Read Articles
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
4 days ago
The link between sleep duration and hypertension risk appears to be mediated by age and body mass index (BMI), a recent study has found.
04 Nov 2019
Multivessel revascularization (MVR) is better than culprit vessel-only revascularization (CVR) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), reports a recent meta-analysis.
Naomi Rodrig, 04 Sep 2017

Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]

Ticagrelor monotherapy noninferior to DAPT plus aspirin in PCI patients

5 days ago

Use of ticagrelor alone among patients who underwent percutaneous coronary intervention (PCI) after 1-month dual antiplatelet therapy (DAPT) has shown noninferiority, but is not superior, to conventional treatment in the prevention of ischaemic events, reports a study. Major bleeding is also comparable between ticagrelor monotherapy and conventional treatment.

A total of 15,991 patients undergoing PCI were randomized to 1-month DAPT followed by 23-month ticagrelor monotherapy or conventional 12-month DAPT followed by 12-month aspirin.

The authors conducted a prespecified ancillary study to assess whether experimental therapy was noninferior, and if met, superior, to conventional treatment for the coprimary efficacy endpoint of all-cause mortality, nonfatal myocardial infarction (MI), nonfatal stroke or urgent target vessel revascularization and superior in preventing BARC (Bleeding Academic Research Consortium) 3 or 5 bleeding (coprimary safety endpoint) at 2 years with a 0.025 significance level to preserve nominal 5 percent alpha error.

Investigator-reported and eventually unreported events of 7,585 patients from the 20 top-enrolling participating sites were resolved by an independent clinical event committee.

The 2-year coprimary efficacy endpoint occurred in 271 (7.14 percent) patients in the ticagrelor group and in 319 (8.41 percent) patients in the conventional group (rate ratio [RR], 95 percent confidence interval [CI], 0.72–0.99), achieving noninferiority of the former (p<0.001) but not superiority (p=0.0465). No between-group difference was seen in the rates of BARC 3 or 5 bleeding (RR, 1.00, 95 percent CI, 0.75–1.33; p=0.986).

There was a time-dependent treatment effect in the ticagrelor group, which correlated with a reduced risk of MI (RR, 0.54, 95 percent CI, 0.33–0.88; p=0.062) and definite stent thrombosis (RR, 014, 0.03–0.63; p=0.007) after 1-year post-PCI.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
4 days ago
The link between sleep duration and hypertension risk appears to be mediated by age and body mass index (BMI), a recent study has found.
04 Nov 2019
Multivessel revascularization (MVR) is better than culprit vessel-only revascularization (CVR) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), reports a recent meta-analysis.
Naomi Rodrig, 04 Sep 2017

Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]